[ACC2017]RESET-HCM研究:中等强度运动改善肥厚型心肌病患者的运动能力

2017-03-21 佚名 国际循环

2017年3月17日,第66届美国心脏病学学会年会(ACC2017)在美国华盛顿盛大开幕。来自密歇根大学医学院的Sara Saberi博士和ACC与会者分享了一项重要的RCT研究,揭示中等强度的运动训练可改善肥厚型心肌病(HCM)患者的运动能力,同时并不增加不良事件的发生。



2017年3月17日,第66届美国心脏病学学会年会(ACC2017)在美国华盛顿盛大开幕。来自密歇根大学医学院的Sara Saberi博士和ACC与会者分享了一项重要的RCT研究,揭示中等强度的运动训练可改善肥厚型心肌病(HCM)患者的运动能力,同时并不增加不良事件的发生。

该研究共纳入左室肥厚≥15 mm的18~80岁患者136例(平均年龄50岁,40%为女性),按1:1随机分配为16周的中等强度运动训练组(n=67)或常规护理组(n=69)。由患者的基础心肺运动试验得出基线心率储备,从而制定一项结构化的、以家庭为导向的个体化运动训练项目,其中,运动方式以步行/慢跑、游泳、骑自行车和椭圆机使用为主。

该研究共随访16周,主要终点事件为第16周与基线相比的峰值耗氧量(peak VO2)的变化,次要终点事件为左室肥大和功能改变,核素心肌显像所示的瘢痕体积变化,BNP值变化,左室流出道梯度变化及生活质量评估。探索性终点为非致死性心律失常、室性早搏(PVC)负荷等,研究的不良事件主要包括晕厥及肌肉骨骼损伤。

研究中基线情况及主要终点、次要终点及不良事件结果差异如下图所示。主要终点事件即peak VO2变化在中等强度运动训练组和常规护理组间有明显差异(1.35 ml/kg/min vs. 0.08 ml/kg/min,平均相差1.27ml/kg/min,95%CI 0.17~2.37,P=0.02),中等强度运动训练组的peak VO2绝对值增加6%。次要终点事件中,SF-36量表评估的生理功能在中等强度训练组有显着改善(组间差异为8.2,95%CI 2.6-13.7,P=0.004)。在心脏形态、左室流出道梯度及BNP值变化上两组间差异无统计学意义(P>0.05)。此外,运动训练组PVC负荷显着减少(P=0.04)。综上,该研究认为4个月的运动锻炼将明显改善患者的peak VO2 和生活质量。

该项研究表明肥厚型心肌病患者进行中等强度的运动训练能够改善运动能力,同时不增加不良事件发生,并且对于室性早搏负荷及整体生活质量都有获益。临床实践中医生往往不建议肥厚型心肌病患者进行体育锻炼,因此该研究结果对于临床治疗具有非常重要的意义,为临床医生对于此类疾病患者的生活指导提供了一些重要依据,但仍需要其他随访时间更长的大型临床试验对安全性终点进行研究。

应当注意的是,该试验中具有高风险特征的患者比例较少,如静息状态下梗阻梯度较大的患者、有症状的肥厚型心肌病患者及在MRI上钆延迟增强显示的患者;同时,该研究也没有对该类患者参与高强度和竞争性运动的适合性进行相关评估。

总之,RESET-HCM研究提示中等强度运动训练能够在不增加不良事件的基础上改善肥厚型心肌病患者的运动能力,但仍需要大型临床试验对安全性等方面进行研究。如果运动确实对这类患者产生获益,那它将成为最好的药物。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793267, encodeId=81421e93267db, content=<a href='/topic/show?id=1a5d153431b' target=_blank style='color:#2F92EE;'>#RESET-HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15343, encryptionId=1a5d153431b, topicName=RESET-HCM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Nov 07 23:49:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325347, encodeId=82c2132534ee3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478111, encodeId=f95514e811151, content=<a href='/topic/show?id=f51a8556cc' target=_blank style='color:#2F92EE;'>#HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8556, encryptionId=f51a8556cc, topicName=HCM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499978, encodeId=e77a14999e8c2, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622256, encodeId=4caa162225618, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793267, encodeId=81421e93267db, content=<a href='/topic/show?id=1a5d153431b' target=_blank style='color:#2F92EE;'>#RESET-HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15343, encryptionId=1a5d153431b, topicName=RESET-HCM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Nov 07 23:49:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325347, encodeId=82c2132534ee3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478111, encodeId=f95514e811151, content=<a href='/topic/show?id=f51a8556cc' target=_blank style='color:#2F92EE;'>#HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8556, encryptionId=f51a8556cc, topicName=HCM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499978, encodeId=e77a14999e8c2, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622256, encodeId=4caa162225618, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793267, encodeId=81421e93267db, content=<a href='/topic/show?id=1a5d153431b' target=_blank style='color:#2F92EE;'>#RESET-HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15343, encryptionId=1a5d153431b, topicName=RESET-HCM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Nov 07 23:49:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325347, encodeId=82c2132534ee3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478111, encodeId=f95514e811151, content=<a href='/topic/show?id=f51a8556cc' target=_blank style='color:#2F92EE;'>#HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8556, encryptionId=f51a8556cc, topicName=HCM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499978, encodeId=e77a14999e8c2, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622256, encodeId=4caa162225618, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
    2017-03-23 仁者大医
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793267, encodeId=81421e93267db, content=<a href='/topic/show?id=1a5d153431b' target=_blank style='color:#2F92EE;'>#RESET-HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15343, encryptionId=1a5d153431b, topicName=RESET-HCM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Nov 07 23:49:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325347, encodeId=82c2132534ee3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478111, encodeId=f95514e811151, content=<a href='/topic/show?id=f51a8556cc' target=_blank style='color:#2F92EE;'>#HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8556, encryptionId=f51a8556cc, topicName=HCM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499978, encodeId=e77a14999e8c2, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622256, encodeId=4caa162225618, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1793267, encodeId=81421e93267db, content=<a href='/topic/show?id=1a5d153431b' target=_blank style='color:#2F92EE;'>#RESET-HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15343, encryptionId=1a5d153431b, topicName=RESET-HCM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Nov 07 23:49:00 CST 2017, time=2017-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325347, encodeId=82c2132534ee3, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478111, encodeId=f95514e811151, content=<a href='/topic/show?id=f51a8556cc' target=_blank style='color:#2F92EE;'>#HCM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8556, encryptionId=f51a8556cc, topicName=HCM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499978, encodeId=e77a14999e8c2, content=<a href='/topic/show?id=a40c9421969' target=_blank style='color:#2F92EE;'>#运动能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94219, encryptionId=a40c9421969, topicName=运动能力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=058e9400974, createdName=xzw116, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622256, encodeId=4caa162225618, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Mar 23 02:49:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]

相关资讯

[ACC2017]LEVO-CTS:左西孟旦在心脏手术中的作用

华盛顿时间3月19日早8点,来自第66届ACC年会上发布的一项最新临床研究——LEVO-CTS表明,心脏手术时,心衰治疗药物左西孟旦作为一种预防措施,不显著降低死亡率、心脏病发作率、肾透析率以及低心输出量综合征高危患者的机械辅助装置使用率。该研究同期发表于《新英格兰医学杂志》。